Endocrine Deep Dives

Avsnitt

• 
  The Discovery of Insulin 19.08.2026 24min

  This episode details the historic journey toward the discovery of insulin, transitioning from a period when a Type 1 diabetes diagnosis was an inevitable death sentence to a new era of medical management. It follows the collaborative yet often volatile efforts of Frederick Banting, Charles Best, J.J.R. Macleod, and James Collip, who successfully isolated the life-saving hormone at the University of Toronto in the early 1920s. The narrative emphasizes the critical evolution of their work, moving from Banting's initial surgical hypothesis involving canine subjects to the biochemical purification necessary for human treatment. The text also highlights the group's humanitarian ethics in patenting the discovery for only three dollars to ensure global accessibility. Furthermore, it addresses the Nobel Prize controversy and internal disputes that complicated the team's legacy for decades. Finally, the overview connects these early breakthroughs to modern advancements like recombinant DNA technology and automated delivery systems, underscoring the profound lasting impact of their research.
• 
  The Life and Work of Jean-Martin Charcot 18.08.2026 24min

  This podcast covers the influential career of Jean-Martin Charcot, the nineteenth-century physician who founded modern clinical neurology at the Salpêtrière hospital in Paris. By applying a rigorous anatomoclinical method, Charcot successfully identified and mapped various conditions, including Multiple Sclerosis, ALS, and Parkinson’s disease. The narrative details his transition from a master of physical pathology to a pioneer in the study of hysteria and hypnosis, which laid the intellectual groundwork for psychoanalysis. While his neurological discoveries remain medical cornerstones, his work on psychological disorders is presented as a complex mixture of brilliant insight and institutional bias. Ultimately, the source portrays Charcot as a transformative figure who elevated the observation of symptoms into a precise scientific discipline.
• 
  Hyperparathyroidism vs Idiopathic Hypercalciurea 17.08.2026 13min

  This episode compares normocalcemic and hyperparathyroidism and idiopathic hypercalciuria, two primary drivers of hypercalciuria and nephrolithiasis. We contrast primary hyperparathyroidism, an autonomous parathyroid oversecretion causing elevated parathyroid hormone and true hypercalcemia, with idiopathic hypercalciuria, where serum calcium remains strictly normal despite excessive urinary calcium excretion.
• 
  Parathyroid Localization 14.08.2026 21min

  This episode reviews the diagnostic strategies for parathyroid localization in primary hyperparathyroidism, guiding the practicing endocrinologist through the selection of optimal imaging modalities. We compare the utility of standard ultrasound and technetium-99m sestamibi scintigraphy with the high sensitivity of modern four-dimensional computed tomography scans. Finally, we discuss how accurate preoperative mapping minimizes operative times and enables focused, minimally invasive parathyroidectomy, translating complex anatomical imaging into successful surgical outcomes at the bedside.
• 
  Diabetes ICD-10 Coding 13.08.2026 17min

  This episode breaks down the intricacies of ICD-10 coding for type 2 diabetes mellitus, providing a practical framework for the practicing endocrinologist. We review the essential code structures under the E11 category, emphasizing the critical need to document specific manifestations, secondary complications, and long-term insulin use.
• 
  Vit D3 + K2? 12.08.2026 20min

  This episode explores the physiological synergy of combining vitamin D3 and vitamin K2 for optimal bone and cardiovascular health. We examine how vitamin D3 enhances intestinal calcium absorption, while vitamin K2 acts as a traffic director by activating osteocalcin and matrix Gla protein. This ensures that the newly absorbed calcium is directed into the bone matrix rather than being pathologically deposited in the arterial walls, providing a balanced approach to micronutrient supplementation in clinical practice.
• 
  Thyrotoxic Periodic Paralysis 11.08.2026 24min

  This episode examines thyrotoxic periodic paralysis, a dangerous but reversible complication of hyperthyroidism characterized by acute muscle weakness and hypokalemia. We break down the underlying three-hit pathophysiology, where excess thyroid hormone upregulates the sodium-potassium pump, genetic mutations impair outward potassium channels, and an environmental trigger like insulin or epinephrine induces a massive intracellular potassium shift. Finally, we review acute management using nonselective beta-blockers and definitive therapies to restore euthyroidism.
• 
  Wolff-Chaikoff and Jod-Basedow 10.08.2026 21min

  This episode explores the complex relationship between iodine and the thyroid gland, focusing on the Wolff-Chaikoff effect and the Jod-Basedow phenomenon. We break down the molecular mechanisms of iodine-induced thyroid suppression, the critical sodium-iodide symporter downregulation that allows normal tissue to escape prolonged hypothyroidism, and the triggers for iodine-induced thyrotoxicosis in autonomous glands. Finally, we review the management of modern triggers like contrast media, amiodarone, and therapeutic applications in thyroid storm.
• 
  Marine-Lenhart Syndrome 07.08.2026 22min

  This episode explores Marine-Lenhart syndrome, a rare variant of thyrotoxicosis where Graves disease and autonomous thyroid nodules coexist within the same gland. We examine the dual mechanism of thyrotropin receptor activation, contrasting extrinsic antibody stimulation with permanent, somatic mutations. The discussion covers the clinical challenges this creates, including the classic scintigraphic unmasking of nodules, resistance to standard radioiodine therapy, and the compounding malignancy risks that make total thyroidectomy a preferred definitive management strategy.
• 
  Spongiform Thyroid Nodules 06.08.2026 19min

  This episode explores spongiform thyroid nodules, a distinct sonographic pattern characterized by microcystic spaces that occupy more than half of the nodule volume. We break down the pathology of these colloid-filled hyperplastic follicles, which carry an exceptionally low malignancy risk of less than two percent. The discussion reviews classification across major guideline systems, conservative management thresholds, and why this highly reliable indicator of benign disease can independently rule out the need for fine-needle aspiration biopsy.
• 
  Drug Effects on Deiodinases 05.08.2026 19min

  This episode examines how common medications alter thyroid hormone economy by targeting the iodothyronine deiodinase enzyme system. We contrast propylthiouracil, which selectively blocks type one deiodinase through a covalent mechanism, with amiodarone, which powerfully inhibits both type one and type two deiodinases to alter systemic feedback. Finally, we review the lipophilicity dependent effects of propranolol and the multi level impact of glucocorticoids, providing a rational framework for managing thyroid storm and interpreting complex laboratory profiles.
• 
  Consumptive Hypothyroidism 04.08.2026 21min

  This episode examines consumptive hypothyroidism, a rare paraneoplastic syndrome driven by the accelerated degradation of thyroid hormones. We discuss how vascular and mesenchymal tumors, such as infantile hepatic hemangiomas and gastrointestinal stromal tumors, aberrantly overexpress the inactivating enzyme type three iodothyronine deiodinase. The discussion covers the classic biochemical profile of elevated thyroid stimulating hormone and markedly increased reverse triiodothyronine, alongside the aggressive, high-dose hormone replacement strategies and tumor-targeted interventions required to successfully restore systemic euthyroidism.
• 
  NTI Syndrome 03.08.2026 20min

  This episode demystifies non-thyroidal illness syndrome, breaking down the dramatic shifts in thyroid hormone economy that occur during systemic illness. We discuss the acute phase, where suppressed type one deiodinase and upregulated type three deiodinase cause a rapid drop in triiodothyronine and a rise in reverse triiodothyronine. Finally, we examine how chronic illness triggers central hypothalamic-pituitary-thyroid axis suppression, keeping thyroid stimulating hormone paradoxically normal or low, and outline the distinct hormonal rebound seen during recovery.
• 
  Graves vs Hashitoxicosis 31.07.2026 24min

  This episode explores the autoimmune thyroid disease spectrum, detailing the clinical overlap and physiological distinctions between Graves disease and Hashimoto thyroiditis. We contrast the active thyroid hormone overproduction driven by stimulating thyrotropin receptor antibodies in true hyperthyroidism with the transient, destructive hormone release seen in hashitoxicosis. The discussion reviews diagnostic strategies using antibody assays, radioactive iodine uptake scans, and triiodothyronine to thyroxine ratios to accurately differentiate these overlapping conditions and guide their appropriate clinical management.
• 
  Nuclear Thyroid Imaging 30.07.2026 21min

  This episode evaluates the clinical utility of technetium-99m, iodine-123, and iodine-131 in thyroid imaging and therapy. We compare technetium-99m, trapped but not organified by the sodium-iodide symporter, with iodine-123, the preferred isotope for diagnostic uptake and high-resolution scanning. Finally, we look at iodine-131, which is reserved primarily for targeted thyroid ablation due to its high-energy beta emission, providing a clear framework for selecting the appropriate radiotracer based on diagnostic or therapeutic clinical goals.
• 
  A history of prolactin 29.07.2026 16min

  This episode charts the century-long history of prolactin research, tracing how scientists mapped its complex neuroendocrine regulation. We begin with the discovery of its lactogenic properties in 1928 and the paradigm-shifting realization that the hypothalamus exerts tonic inhibition over its release via tuberoinfundibular dopamine neurons. The discussion covers the identification of stimulatory factors like thyrotropin-releasing hormone, estrogen, and oxytocin, the molecular characterization of short-loop negative feedback, and its modern reemergence as a vital metabolic regulator.
• 
  Why do we have the hypothalamus 29.07.2026 22min

  This episode examines why the body maintains two distinct neuroendocrine centers in the brain. The hypothalamus acts as a neural-to-endocrine transducer, converting complex electrical inputs from the brain into a chemical language. Using a private hypophyseal portal vascular system, it delivers releasing hormones directly to the nearby anterior pituitary. Rather than a redundant relay, the pituitary provides massive signal amplification, integrates multi-hormonal inputs, and decodes pulsatile signals to manage peripheral organs.
• 
  Thyroid Deiodinases 27.07.2026 20min

  This episode explores how the body processes thyroxine to customize thyroid hormone action at the cellular level. We examine how the single circulating pool of prohormone follows one of two peripheral pathways to arrive at its final destination, diiodothyronine. By choosing whether outer-ring activation or inner-ring inactivation occurs first, type one, type two, and type three iodothyronine deiodinases grant individual tissues autonomous, tissue-specific metabolic control without disturbing systemic concentrations.
• 
  OSA 27.07.2026 24min

  Obstructive sleep apnea represents a critical yet frequently underdiagnosed secondary driver of metabolic dysfunction and endocrine pathology. This episode explores the complex bidirectional relationship between nocturnal hypoxia and endocrine systems, detailing how sleep fragmentation disrupts the hypothalamic-pituitary-adrenal axis, elevates cortisol levels, and induces severe insulin resistance.
• 
  Insulin tolerance test 24.07.2026 20min

  The insulin tolerance test remains the gold standard for evaluating suspected growth hormone deficiency and secondary adrenal insufficiency. By administering intravenous insulin to deliberately induce hypoglycemia, clinicians can provoke and assess the hypothalamic-pituitary-adrenal axis response. This episode breaks down the physiological mechanisms behind the test, outlines strict patient safety protocols, and discusses how to interpret cortisol and growth hormone nadirs to establish an accurate clinical diagnosis in complex endocrine cases.